SM 2235
Alternative Names: SM-2235Latest Information Update: 15 Jun 2024
At a glance
- Originator Beijing StarMab BioMed Technology
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Adverse events and pharmacodynamics data from a preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 31 Oct 2023 Preclinical trials in Solid tumours in China (Parenteral) (Beijing StarMab Biomed Technology pipeline; October 2023).)